Literature DB >> 28357567

Emetine induces estrogen receptor alpha degradation and prevents 17β-estradiol-induced breast cancer cell proliferation.

Claudia Busonero1, Stefano Leone1, Filippo Acconcia2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28357567     DOI： 10.1007/s13402-017-0322-z

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN： 2211-3428            Impact factor:   6.730


× No keyword cloud information.
  9 in total

Review 1.  Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds.

Authors:  Roberto Würth; Stefano Thellung; Adriana Bajetto; Michele Mazzanti; Tullio Florio; Federica Barbieri
Journal:  Drug Discov Today       Date:  2015-10-09       Impact factor: 7.851

2.  Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.

Authors:  Donald P McDonnell; Suzanne E Wardell; John D Norris
Journal:  J Med Chem       Date:  2015-06-03       Impact factor: 7.446

3.  A pragmatic approach to the analysis of DNA histograms with a definable G1 peak.

Authors:  J V Watson; S H Chambers; P J Smith
Journal:  Cytometry       Date:  1987-01

Review 4.  Xenoestrogen regulation of ERα/ERβ balance in hormone-associated cancers.

Authors:  Filippo Acconcia; Marco Fiocchetti; Maria Marino
Journal:  Mol Cell Endocrinol       Date:  2016-11-02       Impact factor: 4.102

Review 5.  The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.

Authors:  Eva Ciruelos; Tomás Pascual; María Luisa Arroyo Vozmediano; Marta Blanco; Luis Manso; Lucía Parrilla; Cesar Muñoz; Estela Vega; Monica Jackelin Calderón; Blanca Sancho; Hernán Cortes-Funes
Journal:  Breast       Date:  2014-03-01       Impact factor: 4.380

6.  Emetine ditartrate: a possible lead for emergency contraception.

Authors:  P K Mehrotra; S Kitchlu; A Dwivedi; P K Agnihotri; S Srivastava; R Roy; A P Bhaduri
Journal:  Contraception       Date:  2004-05       Impact factor: 3.375

7.  Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties.

Authors:  Elisabet Cuyàs; Begoña Martin-Castillo; Bruna Corominas-Faja; Anna Massaguer; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

8.  A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer.

Authors:  Hsiao-Rong Chen; David H Sherr; Zhenjun Hu; Charles DeLisi
Journal:  BMC Med Genomics       Date:  2016-07-30       Impact factor: 3.063

9.  Dynamin II is required for 17β-estradiol signaling and autophagy-based ERα degradation.

Authors:  Pierangela Totta; Claudia Busonero; Stefano Leone; Maria Marino; Filippo Acconcia
Journal:  Sci Rep       Date:  2016-03-24       Impact factor: 4.379
  9 in total
  10 in total

1.  Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.

Authors:  Shiyi Yu; Xue Gong; Zhifang Ma; Meng Zhang; Ling Huang; Jun Zhang; Shuang Zhao; Tao Zhu; Zhenghong Yu; Liming Chen
Journal:  Cell Oncol (Dordr)       Date:  2019-11-07       Impact factor: 6.730

2.  Concomitant high expression of ERα36, GRP78 and GRP94 is associated with aggressive papillary thyroid cancer behavior.

Authors:  Yu-Jie Dai; Yi-Bo Qiu; Rong Jiang; Man Xu; Ling-Yao Liao; George G Chen; Zhi-Min Liu
Journal:  Cell Oncol (Dordr)       Date:  2018-01-24       Impact factor: 6.730

3.  In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.

Authors:  Claudia Busonero; Stefano Leone; Fabrizio Bianchi; Filippo Acconcia
Journal:  Cell Oncol (Dordr)       Date:  2018-09-04       Impact factor: 6.730

4.  PRMT1 promotes pancreatic cancer growth and predicts poor prognosis.

Authors:  Chao Song; Tianwei Chen; Lan He; Ning Ma; Jian-Ang Li; Ye-Fei Rong; Yuan Fang; Mengmeng Liu; Dong Xie; Wenhui Lou
Journal:  Cell Oncol (Dordr)       Date:  2019-09-13       Impact factor: 6.730

5.  Unexpected Impact of a Hepatitis C Virus Inhibitor on 17β-Estradiol Signaling in Breast Cancer.

Authors:  Stefania Bartoloni; Stefano Leone; Filippo Acconcia
Journal:  Int J Mol Sci       Date:  2020-05-12       Impact factor: 5.923

6.  Transcriptome analysis and connectivity mapping of Cissampelos pareira L. provides molecular links of ESR1 modulation to viral inhibition.

Authors:  Madiha Haider; Dhwani Dholakia; Aleksha Panwar; Parth Garg; Atish Gheware; Dayanidhi Singh; Khushboo Singhal; Shaunak A Burse; Surekha Kumari; Anmol Sharma; Arjun Ray; Guruprasad R Medigeshi; Upendra Sharma; Bhavana Prasher; Mitali Mukerji
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

7.  Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.

Authors:  Sara Pescatori; Stefano Leone; Manuela Cipolletti; Stefania Bartoloni; Alessandra di Masi; Filippo Acconcia
Journal:  J Exp Clin Cancer Res       Date:  2022-04-13

8.  The antiviral drug telaprevir induces cell death by reducing FOXA1 expression in estrogen receptor α (ERα)-positive breast cancer cells.

Authors:  Stefania Bartoloni; Stefano Leone; Sara Pescatori; Manuela Cipolletti; Filippo Acconcia
Journal:  Mol Oncol       Date:  2022-09-03       Impact factor: 7.449

9.  Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.

Authors:  Filippo Acconcia
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

10.  Targeting proteasome-associated deubiquitinases as a novel strategy for the treatment of estrogen receptor-positive breast cancer.

Authors:  Xiaohong Xia; Yuning Liao; Zhiqiang Guo; Yanling Li; Lili Jiang; Fangcheng Zhang; Chuyi Huang; Yuan Liu; Xuejun Wang; Ningning Liu; Jinbao Liu; Hongbiao Huang
Journal:  Oncogenesis       Date:  2018-09-24       Impact factor: 7.485
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.